StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report sent to investors on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 7.4 %

Shares of CARA stock opened at $0.31 on Monday. The firm has a market cap of $16.97 million, a price-to-earnings ratio of -0.13 and a beta of 0.70. Cara Therapeutics has a 12 month low of $0.24 and a 12 month high of $1.40. The stock has a 50-day moving average price of $0.29 and a 200 day moving average price of $0.43.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. Sell-side analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Cara Therapeutics

A hedge fund recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC bought a new stake in Cara Therapeutics, Inc. (NASDAQ:CARA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned 0.17% of Cara Therapeutics at the end of the most recent quarter. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.